



UK Health  
Security  
Agency

# **COVID-19 vaccine surveillance report**

## **Week 40**

# Contents

Summary.....	3
Vaccine effectiveness.....	3
Population impact.....	3
Vaccine effectiveness .....	4
Effectiveness against symptomatic disease .....	4
Effectiveness against hospitalisation .....	5
Effectiveness against mortality .....	5
Effectiveness against infection .....	5
Effectiveness against transmission .....	6
Population impact .....	8
Vaccine coverage .....	8
Vaccination status .....	11
Vaccine impact on proportion of population with antibodies to COVID-19.....	19
Summary of impact on hospitalisations, infections and mortality.....	24
References.....	25

## Summary

Four coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorous clinical trials have been undertaken to understand the immune response, safety profile and efficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccines as they are rolled out in the population is important to continually ensure that clinical and public health guidance on the vaccination programme is built upon the best available evidence.

UK Health Security Agency, UKHSA, formerly Public Health England (PHE), works closely with the Medicines and Healthcare Regulatory Agency (MHRA), NHS England, and other government, devolved administration and academic partners to monitor the COVID-19 vaccination programme. Details of the vaccine surveillance strategy are set on the page [COVID-19: vaccine surveillance strategy \(1\)](#). As with all vaccines, the safety of COVID-19 vaccines is continuously [being monitored by the MHRA](#). They conclude that overall, the benefits of COVID-19 vaccines outweigh any potential risks [\(2\)](#).

## Vaccine effectiveness

Several studies of vaccine effectiveness have been conducted in the UK which indicate that 2 doses of vaccine are between 65 and 95% effective at preventing symptomatic disease with COVID-19 with the Delta variant, with higher levels of protection against severe disease including hospitalisation and death. There is some evidence of waning of protection against infection and symptomatic disease over time, though protection against severe disease remains high in most groups at least 5 months after the second dose.

## Population impact

The impact of the vaccination programme on the population is assessed by taking into account vaccine coverage, evidence on vaccine effectiveness and the latest COVID-19 disease surveillance indicators. Vaccine coverage tells us about the proportion of the population that have received 1 and 2 doses of COVID-19 vaccines. By 3 October 2021, the overall vaccine uptake in England for dose 1 was 65.3% and 60.1% for dose 2. In line with the programme rollout, coverage is highest in the oldest age groups.

We present data on COVID-19 cases, hospitalisations and deaths by vaccination status.

Based on antibody testing of blood donors, 98.0% of the adult population now have antibodies to COVID-19 from either infection or vaccination compared to 19.0% that have antibodies from infection alone. Over 96% of adults aged 17 or older have antibodies from either infection or vaccination.

## Vaccine effectiveness

Large clinical trials have been undertaken for each of the COVID-19 vaccines approved in the UK which found that they are highly efficacious at preventing symptomatic disease in the populations that were studied. The clinical trials have been designed to be able to assess the efficacy of the vaccine against laboratory confirmed symptomatic disease with a relatively short follow up period so that effective vaccines can be introduced as rapidly as possible.

Nevertheless, understanding the effectiveness against different outcomes (such as severe disease and onwards transmission), effectiveness in different subgroups of the population and understanding the duration of protection are equally important in decision making around which vaccines should be implemented as the programme evolves, who they should be offered to and whether booster doses are required.

Vaccine effectiveness is estimated by comparing rates of disease in vaccinated individuals to rates in unvaccinated individuals. Below we outline the latest real-world evidence on vaccine effectiveness from studies in UK populations. We focus on data related to the Delta variant which is currently dominant in the UK. The findings are also summarised in [Table 1](#).

## Effectiveness against symptomatic disease

Vaccine effectiveness against symptomatic COVID-19 has been assessed in England based on community testing data linked to vaccination data from the National Immunisation Management System (NIMS), cohort studies such as the COVID Infection Survey and GP electronic health record data. After 2 doses, observed vaccine effectiveness against symptomatic disease with the Delta variant reaches approximately 65 to 70% with AstraZeneca Vaxzevria and 80 to 95% with Pfizer-BioNTech Comirnaty and Moderna Spikevax ([3](#), [4](#)) Vaccine effectiveness is generally slightly higher in younger compared to older age groups. With both Vaxzevria and Comirnaty, there is evidence of waning of protection over time, most notably among older adults. There is not yet enough follow-up with Spikevax to assess waning ([3](#)).

Data (based primarily on the Alpha variant) suggest that in most clinical risk groups, immune response to vaccination is maintained and high levels of VE are seen with both the Pfizer and AstraZeneca vaccines. Reduced antibody response and vaccine effectiveness were seen after 1 dose of vaccine among the immunosuppressed group, however, after a second dose the reduction in vaccine effectiveness is smaller ([5](#)).

Analyses by dosing interval suggest that immune response to vaccination and vaccine effectiveness against symptomatic disease improves with a longer (greater than 6 week interval) compared to a shorter interval of 3 to 4 weeks ([6](#), [3](#))

## Effectiveness against hospitalisation

Several studies have estimated vaccine effectiveness against hospitalisation in older all of which indicate higher levels of protection against hospitalisation with all vaccines against the Alpha variant ([7](#), [8](#), [9](#), [10](#)). Effectiveness against hospitalisation of over 90% is also observed with the Delta variant with all 3 vaccines ([3](#)). In most groups there is relatively limited waning of protection against hospitalisation over a period of at least 5 months after the second dose. Greater waning appears to occur among those in clinical risk groups ([3](#)).

## Effectiveness against mortality

High levels of protection (over 90%) are also seen against mortality with all 3 vaccines and against both the Alpha and Delta variants ([7](#), [11](#), [3](#)). Relatively limited waning of protection against mortality is seen over a period of at least 5 months.

## Effectiveness against infection

Although individuals may not develop symptoms of COVID-19 after vaccination, it is possible that they could still be infected with the virus and could transmit to others. Understanding how effective vaccines are at preventing infection is therefore important to predict the likely impact of the vaccination programme on the wider population. In order to estimate vaccine effectiveness against infection, repeat asymptomatic testing of a defined cohort of individuals is required. Studies have now reported on vaccine effectiveness against infection in healthcare workers, care home residents and the general population ([12](#), [13](#), [14](#), [15](#)). With the delta variant, vaccine effectiveness against infection has been estimated at around 65% with Vaxzevria and 80% with Comirnaty ([4](#)).

## Effectiveness against transmission

As described above, several studies have provided evidence that vaccines are effective at preventing infection. Uninfected individuals cannot transmit; therefore, the vaccines are also effective at preventing transmission. There may be additional benefit, beyond that due to prevention of infection, if some of those individuals who become infected despite vaccination are also at a reduced risk of transmitting (for example, because of reduced duration or level of viral shedding). A household transmission study in England found that household contacts of cases vaccinated with a single dose had approximately 35 to 50% reduced risk of becoming a confirmed case of COVID-19. This study used routine testing data so would only include household contacts that developed symptoms and went on to request a test via pillar 2. It cannot exclude asymptomatic secondary cases or mildly symptomatic cases who chose not to request a COVID-19 test (16). Data from Scotland has also shown that household contacts of vaccinated healthcare workers are at reduced risk of becoming a case, which is in line with the studies on infection (17). Both of these studies relate to a period when the Alpha variant dominated. An analysis from the ONS Community Infection Survey found that contacts of vaccinated index cases had around 65-80% reduced odds of testing positive with the Alpha variant and 35-65% reduced odds of testing positive with the Delta variant compare to contacts of unvaccinated index cases (18).

A summary of vaccine effectiveness evidence can be seen in Table 1.

**Table 1. Summary of evidence on vaccine effectiveness against different outcomes Delta**

Outcome	Vaccine effectiveness*		
	Pfizer-BioNTech Cominarty	AstraZeneca Vaxzevria	Moderna Spikevax
Infection	75-85%	60-70%	
Symptomatic disease	80-90%	65-75%	90-99%
Hospitalisation	95-99%	90-99%	95-99%
Mortality	90-99%	90-95%	

High Confidence	Evidence from multiple studies which is consistent and comprehensive
Medium Confidence	Evidence is emerging from a limited number of studies or with a moderately level of uncertainty
Low Confidence	Little evidence is available at present and results are inconclusive

\* Estimates of initial vaccine effectiveness in the general population after a 2 dose course. This typically applies for at least the first 3 to 4 months after vaccination. For some outcomes there may be waning of effectiveness beyond this point.

## Population impact

Vaccines typically have both direct effects on those who are vaccinated and indirect effects on the wider population due to a reduced probability that people will come into contact with an infected individual. The overall impact of the vaccination programme may therefore extend beyond that estimated through vaccine effectiveness analysis.

Estimating the impact of a vaccination programme is challenging as there is no completely unaffected control group. Furthermore, the effects of the vaccination programme need to be differentiated from that of other interventions (for example, lockdowns or outbreak control measures), changes in behaviour and any seasonal variation in COVID-19 activity.

UKHSA and other government and academic partners monitor the impact of the of the vaccination programme on levels of COVID-19 antibodies in the population and different disease indicators, including hospitalisations and mortality. This is done through population-based testing and through modelling which combines vaccine coverage rates in different populations, estimates of vaccine effectiveness and disease surveillance indicators.

## Vaccine coverage


The data in this week's report covers the period from 8 December 2020 to 3 October 2021 (week 39) ([Figure 1](#)). It shows the provisional number and percentage of people in England who have had received 1 dose or 2 doses of a COVID-19 vaccination by age group and week since the start of the programme.

Up to 31 August 2021 81,532 women of child-bearing age in England (under 50) who reported that they were pregnant or could be pregnant at the time, received at least 1 dose of COVID-19 vaccination and of these, 65,579 have received their second dose. This is in response to the self-reported pre-screening question "Are you or could you be pregnant?". The true number of pregnant women who have had a COVID-19 vaccination is likely to be greater than this.


Please note that pregnant women are not a separate priority group as defined by JCVI who have advised that "women who are pregnant should be offered vaccination at the same time as non-pregnant women, based on their age and clinical risk group" therefore comparing vaccine uptake in pregnant women to other vaccination programmes is not currently appropriate. The MHRA closely monitors the safety of COVID-19 vaccine exposures in pregnancy, including Yellow Card reports for COVID-19 vaccines used in pregnancy, for the latest information please see the webpage [Coronavirus vaccine – weekly summary of Yellow Card reporting](#).

**Figure 1. Cumulative weekly vaccine uptake by age**

a) Dose 1



b) Dose 2



## Vaccination status

Vaccination status of COVID-19 cases, deaths and hospitalisations by week of specimen date over the past 4 weeks up to week 39 (up to 3 October 2021) are shown in [Table 2 to 4](#) and [Figure 2](#).

### Methods

COVID-19 cases and deaths identified through routine collection from the Second Generation Surveillance System (SGSS) and from UKHSA EpiCell's deaths data as described [here](#), were linked to the National Immunisation Management System (NIMS) to derive vaccination status, using an individual's NHS number as the unique identifier.

Attendance to emergency care at NHS trusts was derived from the Emergency Care DataSet (ECDS) managed by NHS Digital. The same data source was used to identify COVID-19 cases where the attendance to emergency care resulted in admission to an NHS trust.

ECDS is updated weekly, and cases are linked to these data twice weekly. Data from ECDS are subject to reporting delays as, although NHS trusts may update data daily, the mandatory deadline for submission is by the 21st of every month. This means that for weeks immediately following the 21st of a month, numbers may be artificially low and are likely to be higher in later versions of the report.

Data from ECDS also only report on cases who have been presented to emergency care and had a related overnight patient admission and do not show those who are currently in hospital with COVID-19. As such, it is not appropriate for use for surveillance of those currently hospitalised with COVID-19. In addition, these data will not show cases who were directly admitted as inpatients without presenting to emergency care.

The outcome of overnight inpatient admission following presentation to emergency care, was limited to those occurring within 28 days of the earliest specimen date for a COVID-19 case.

Deaths include those who died (a) within 28 days of the earliest specimen date or (b) within 60 days of the first specimen date or more than 60 days after the first specimen date with COVID-19 mentioned on the death certificate.

The rate of COVID-19 cases, hospitalisation, and deaths in fully vaccinated and unvaccinated groups was calculated using vaccine coverage data for each age group extracted from the National Immunisation Management Service.

## Results

The rate of a positive COVID-19 test varies by age and vaccination status. The rate of a positive COVID-19 test is substantially lower in vaccinated individuals compared to unvaccinated individuals up to the age of 39. In individuals aged greater than 40, the rate of a positive COVID-19 test is higher in vaccinated individuals compared to unvaccinated. This is likely to be due to a variety of reasons, including differences in the population of vaccinated and unvaccinated people as well as differences in testing patterns.

The rate of hospitalisation within 28 days of a positive COVID-19 test increases with age, and is substantially greater in unvaccinated individuals compared to vaccinated individuals.

The rate of death within 28 days or within 60 days of a positive COVID-19 test increases with age, and again is substantially greater in unvaccinated individuals compared to fully vaccinated individuals.

## Interpretation of data

These data should be considered in the context of vaccination status of the population groups shown in the rest of this report. The vaccination status of cases, inpatients and deaths is not the most appropriate method to assess vaccine effectiveness and there is a high risk of misinterpretation. Vaccine effectiveness has been formally estimated from a number of different sources and is described earlier in this report.

In the context of very high vaccine coverage in the population, even with a highly effective vaccine, it is expected that a large proportion of cases, hospitalisations and deaths would occur in vaccinated individuals, simply because a larger proportion of the population are vaccinated than unvaccinated and no vaccine is 100% effective. This is especially true because vaccination has been prioritised in individuals who are more susceptible or more at risk of severe disease. Individuals in risk groups may also be more at risk of hospitalisation or death due to non-COVID-19 causes, and thus may be hospitalised or die with COVID-19 rather than because of COVID-19.

**Table 2. COVID-19 cases by vaccination status between week 36 and week 39 2021**

Cases reported by specimen date between week 36 and week 39 2021	Total	Unlinked*	Not vaccinated	Received one dose (1-20 days before specimen date)	Received one dose, ≥21 days before specimen date	Second dose ≥14 days before specimen date	Rates among persons vaccinated with 2 doses (per 100,000)	Rates among persons not vaccinated (per 100,000)
Under 18	305,428	20,967	272,981	4,973	5,898	609	278.8	2,325.7
18-29	67,820	8,556	23,440	1,119	12,593	22,112	409.6	688.1
30-39	81,532	7,534	21,449	690	7,468	44,391	763.6	738.4
40-49	101,094	6,839	11,662	297	3,653	78,643	1,281.8	690.2
50-59	70,731	4,668	5,144	89	1,464	59,366	839.5	502.5
60-69	36,953	2,585	1,798	26	546	31,998	563.1	332.9
70-79	22,142	1,367	693	6	207	19,869	428.9	281.4
80+	10,581	869	403	4	199	9,106	354.4	319.5

\*individuals whose NHS numbers were unavailable to link to the NIMS

\*\* Interpretation of the case rates in vaccinated and unvaccinated population is particularly susceptible to changes in denominators and should be interpreted with extra caution.

**Table 3. COVID-19 cases presenting to emergency care (within 28 days of a positive specimen) resulting in an overnight inpatient admission by vaccination status between week 36 and week 39 2021**

<b>Cases presenting to emergency care (within 28 days of a positive test) resulting in overnight inpatient admission, by specimen date between week 36 and week 39 2021</b>	<b>Total</b>	<b>Unlinked*</b>	<b>Not vaccinated</b>	<b>Received one dose (1-20 days before specimen date)</b>	<b>Received one dose, ≥21 days before specimen date</b>	<b>Second dose ≥14 days before specimen date</b>	<b>Rates among persons vaccinated with 2 doses (per 100,000)</b>	<b>Rates among persons not vaccinated (per 100,000)</b>
Under 18	486	20	455	3	7	1	0.5	3.9
18-29	348	6	241	6	35	60	1.1	7.1
30-39	588	15	396	5	46	126	2.2	13.6
40-49	769	15	388	9	46	311	5.1	23.0
50-59	870	6	359	3	36	466	6.6	35.1
60-69	963	8	274	4	29	648	11.4	50.7
70-79	1,246	2	173	2	30	1,039	22.4	70.2
80+	1,421	2	125	1	34	1,259	49.0	99.1

\*individuals whose NHS numbers were unavailable to link to the NIMS

**Table 4. COVID-19 deaths (a) within 28 days and (b) within 60 days of positive specimen or with COVID-19 reported on death certificate, by vaccination status between week 36 and week 39 2021**

(a)

<b>Death within 28 days of positive COVID-19 test by date of death between week 36 and week 39 2021</b>	<b>Total</b>	<b>Unlinked*</b>	<b>Not vaccinated</b>	<b>Received one dose (1-20 days before specimen date)</b>	<b>Received one dose, ≥21 days before specimen date</b>	<b>Second dose ≥14 days before specimen date</b>	<b>Rates among persons vaccinated with 2 doses (per 100,000)</b>	<b>Rates among persons not vaccinated (per 100,000)</b>
Under 18	6	3	2	1	0	0	0.0	0.0
18-29	18	1	12	0	0	5	0.1	0.4
30-39	38	2	29	0	0	7	0.1	1.0
40-49	77	3	46	0	5	23	0.4	2.7
50-59	238	6	113	1	12	106	1.5	11.0
60-69	414	7	114	0	22	271	4.8	21.1
70-79	786	3	127	0	22	634	13.7	51.6
80+	1,449	8	168	1	37	1,235	48.1	133.2

(b)


<b>Death within 60 days of positive COVID-19 test by date of death between week 36 and week 39 2021</b>	<b>Total</b>	<b>Unlinked*</b>	<b>Not vaccinated</b>	<b>Received one dose (1-20 days before specimen date)</b>	<b>Received one dose, ≥21 days before specimen date</b>	<b>Second dose ≥14 days before specimen date</b>	<b>Rates among persons vaccinated with 2 doses (per 100,000)</b>	<b>Rates among persons not vaccinated (per 100,000)</b>
Under 18	8	4	3	1	0	0	0.0	0.0
18-29	25	1	16	0	1	7	0.1	0.5
30-39	49	3	34	0	1	11	0.2	1.2
40-49	116	3	73	0	8	32	0.5	4.3
50-59	305	7	146	1	15	136	1.9	14.3
60-69	519	9	150	0	28	332	5.8	27.8
70-79	938	4	147	0	29	758	16.4	59.7
80+	1,711	8	183	1	45	1,474	57.4	145.1

\*individuals whose NHS numbers were unavailable to link to the NIMS


\*\* Number of deaths of people who had had a positive test result for COVID-19 and either died within 60 days of the first positive test or have COVID-19 mentioned on their death certificate

**Figure 2. Rates (per 100,000) by vaccination status from week 36 to week 39 2021**


**(a) COVID-19 cases**




**(b) Cases presenting to emergency care (within 28 days of a positive test) resulting in overnight inpatient admission**



(c) Death within 28 days of positive COVID-19 test



(d) Death within 60 days of positive COVID-19 test



## Vaccine impact on proportion of population with antibodies to COVID-19

UKHSA monitors the proportion of the population with antibodies to COVID-19 by testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection). This is important in helping to understand the extent of spread of COVID-19 infection (including asymptomatic infection) in the population and the impact of the vaccine programme. 250 samples from every geographic region in England are tested each week using 2 different laboratory tests, the Roche nucleoprotein (N) and Roche spike (S) antibody assays. This dual testing helps to distinguish between antibodies that are produced following natural COVID-19 infection and those that develop after vaccination. Nucleoprotein (Roche N) assays only detect post-infection antibodies, whereas spike (Roche S) assays will detect both post-infection antibodies and vaccine-induced antibodies. Thus, changes in the proportion of samples testing positive on the Roche N assay will reflect the effect of natural infection and spread of COVID-19 in the population. Increases in the proportion positive as measured by S antibody will reflect both infection and vaccination. Antibody responses reflect infection or vaccination occurring at least 2 to 3 weeks previously given the time taken to generate an antibody response.

In week 40, errors were identified and corrected in some historical sample records within week 30, first reported in week 32. These records had resulted in some minor variations in age specific Roche N estimates between report weeks 32 and 39, although these were unlikely to alter the interpretation of any trends. Data reported in this week's report have been corrected and the updated historical Roche N seropositivity can be seen in figure 4.

In this report, we present the results using a 4-weekly average, of testing samples up to 24 September 2021, which takes account of the age and geographical distribution of the English population. Overall, the proportion of the population with antibodies using the Roche N and Roche S assays respectively were 19.0% and 98.0% for the period 30 August to 24 September (weeks 35 to 38) ([Figure 3](#)). This compares with 18.6% Roche N seropositivity and 97.8% Roche S seropositivity for the period of 02 August to 29 August (weeks 31 to 34).

The continuing increase in seropositivity using the Roche S assay reflects the growing proportion of adults who have developed antibodies following vaccination.


[Figure 4a and 4b](#) show the proportion of the population with antibodies by age group. Recent increases in N seropositivity has been observed in some age groups. Roche N seropositivity has increased slightly in the 30 to 39 year olds from 20.9% in weeks 31 to 34 to 24.5% in weeks 35 to 38. Similarly, small increases were observed in individuals aged 60 to 69 from 11.3% in weeks 31 to 34 to 12.3% in weeks 35 to 38. Prevalence in those aged 40 to 49 years old has decreased from 19.4% in weeks 31 to 34 to 18.4% in weeks 35 to 38. Similarly, decreases were also observed in 50 to 59 year olds from 19.1% in weeks 31 to 34 to 17.7% in weeks 35 to 38. Prevalence in individuals aged 17 to 29 has remained stable at 28.0% in weeks 31 to 34 and 27.9% in weeks 35 to 38 as well as in individuals aged 70 to 84 between 7.6% in weeks 31 to 34 and 7.5% in weeks 35 to 38. Decreases in Roche N seropositivity may be due to waning of

the N antibody response over time, however it's important to note that confidence intervals overlap.

The pattern of increases in Roche S seropositivity which are observed follow the roll out of the vaccination programme with the oldest age groups offered vaccine first. ([Figure 4b](#)). Roche S seropositivity increased first in donors aged 70 to 84 and has plateaued since week 13, reaching 99.2% in weeks 35 to 38. Seropositivity has also plateaued since week 16 for those aged 60 to 69 reaching 98.7% in weeks 35 to 38. Plateauing in Roche S seropositivity has been observed since week 19 in those aged 50 to 59 reaching 98.8% in weeks 35 to 38 2021. A plateauing in seropositivity has been observed in the 40 to 49-year olds since week 23 reaching 98.6% in weeks 35 to 38. Plateauing has been observed in the 30 to 39 year olds from week 28 reaching 97.4% in weeks 35 to 38. A plateauing in seropositivity has recently been observed in the 17 to 29 year olds reaching 96.3% in weeks 35 to 38 2021.


The impact of the vaccination programme is clearly evident from the increases in the proportion of the adult population with antibodies based on Roche S testing. This was evident initially amongst individuals aged 50 years and above who were prioritised for vaccination as part of the phase 1 programme and since week 15 in younger adults and below as part of phase 2 of the vaccination programme. Roche S seropositivity is now >95% across all adult age groups.


**Figure 3. Overall population weighted 4-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors from the Roche S and Roche N assays.**



**Figure 4. Population weighted 4-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors from the Roche S and Roche N assays by a) age groups 17 to 29, 30 to 39 and 40 to 49, b) age group 50 to 59, 60 to 69 and 70 to 84.**

a)





## Summary of impact on hospitalisations, infections and mortality

UKHSA previously reported on the number of hospitalisations directly averted by vaccination. In total, around 261,500 hospitalisations have been prevented in those aged 45 years and over up to 19 September 2021.

UKHSA and University of Cambridge MRC Biostatistics Unit previously reported on the direct and indirect impact of the vaccination programme on infections and mortality. Estimates suggest that 127,500 deaths and 24,144,000 infections have been prevented as a result of the COVID-19 vaccination programme, up to 24 September.

Neither of these models will be updated going forward. This is due to these models being unable to account for the interventions that would have been implemented in the absence of vaccination. Consequently, over time the state of the actual pandemic and the no-vaccination pandemic scenario have become increasingly less comparable. For further context surrounding this figure and for previous estimates, please see previous vaccine surveillance reports.

## References

1. Public Health England. '[COVID-19: vaccine surveillance strategy 2021](#)'
2. Medicines and Healthcare Products Regulatory Agency. '[Coronavirus vaccine – weekly summary of Yellow Card reporting 2021](#)'
3. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R and others. '[Vaccine effectiveness and duration of protection of Comirnaty, Vaxzervia and Spikevax against mild and severe COVID-19 in the UK](#)'. Khub. 2021.
4. Pouwels K, Pritchard E, Matthews P, Stoesser N, Eyre D and others. '[Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK](#)'. MedRxiv. 2021
5. Whitaker H, Tsang R, Byford R, Andrews N, Sherlock J, Sebastian Pillai P and others. '[Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups](#)'
6. Amirhalingham G, Lopez Bernal J, Andrews N, Whitaker H, Gower C, Stowe J and others. '[Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England](#).' medRxiv. 2021
7. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E and others.  
'Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19-related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.' British Medical Journal 2021: volume 373, n1,088
8. Vasileiou E, Simpson CR, Robertson C, Shi T, Kerr S, Agrawal U and others. 'Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people.' 2021
9. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K and others. '[Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study](#).' Lancet Infectious Diseases 2021
10. Ismail SA, Vilaplana TG, Elgohari S, Stowe J, Tessier E, Andrews N and others. 'Effectiveness of BNT162b2 mRNA and ChAdOx1 adenovirus vector COVID-19 vaccines on risk of hospitalisation among older adults in England: an observational study using surveillance data.' PHE Preprints. 2021
11. Lopez Bernal J, Andrews N, Gower C, Stowe J, Tessier E, Simmons R and others. 'Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19.' PHE Preprints 2021
12. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D and others. 'Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK's COVID-19 Infection Survey.' medRxiv 2021: 2021.04.22.21255913

13. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A and others. [‘COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection \(SIREN\): a prospective, multicentre, cohort study.’](#) Lancet 2021
14. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S and others. [‘Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England \(VIVALDI\): a prospective cohort study.’](#) Lancet Infectious Diseases 2021
15. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P and others. ‘Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.’ The Lancet Infectious Diseases 2021
16. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. [‘Effect of Vaccination on Household Transmission of SARS-CoV-2 in England’](#) NEJM 2021
17. V Shah AS, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R and others. ‘Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households.’ medRxiv 2021: 2021.03.11.21253275
18. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, Walker S, Peto T. [‘The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission’](#) medRxiv 2021: 2021.09.28.21264260

# About the UK Health Security Agency

The UK Health Security Agency is an executive agency, sponsored by the [Department of Health and Social Care](#).

[www.ukhsa.gov.uk](http://www.ukhsa.gov.uk)

© Crown copyright 2021

Published: 7 October 2021  
Publishing reference: GOV-10076

**OGL**

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](#). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.



UKHSA supports the UN  
Sustainable Development Goals

**SUSTAINABLE DEVELOPMENT GOALS**